Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: The European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) performs annual sentinel surveillance of Neisseria gonorrhoeae susceptibility to therapeutically relevant antimicrobials across the European Union/European Economic Area (EU/EEA). We present the Euro-GASP results from 2016 (25 countries), linked to patient epidemiological data, and compared with data from previous years. Methods: Agar dilution and minimum inhibitory concentration (MIC) gradient strip methodologies were used to determine the antimicrobial susceptibility (using EUCAST breakpoints) of 2660 N. gonorrhoeae isolates from 25 countries across the EU/EEA. Significance of differences compared with Euro-GASP results in previous years was analysed using Z-tests. Results: No isolates with resistance to ceftriaxone (MIC > 0.125 mg/L) were detected in 2016 (one in 2015). However, the proportion of isolates with decreased susceptibility to ceftriaxone (MICs from 0.03 mg/L to 0.125 mg/L) increased significantly (p = 0.01) from 2015 to 2016. There were 14 (0.5%) isolates with ceftriaxone MICs 0.125 mg/L (on the resistance breakpoint), of which one isolate was resistant to azithromycin and four showed intermediate susceptibility to azithromycin. Cefixime resistance was detected in 2.1% of isolates in 2016 compared with 1.7% in 2015 (p = 0.26) and azithromycin resistance in 7.5% in 2016 compared with 7.1% in 2015 (p = 0.74). Seven (0.3%) isolates from five countries displayed high-level azithromycin resistance (MIC≥256 mg/L) in 2016 compared with five (0.2%) isolates in 2015. Resistance rate to ciprofloxacin was 46.5% compared with 49.4% in 2015 (p = 0.06). No isolates were resistant to spectinomycin and the MICs of gentamicin remained stable compared with previous years. Conclusions: Overall AMR rates in gonococci in EU/EEA remained stable from 2015 to 2016. However, the ceftriaxone MIC distribution shifted away from the most susceptible (≤0.016 mg/L) and the proportion of isolates with decreased susceptibility to ceftriaxone increased significantly. This development is of concern as current European gonorrhoea management guideline recommends ceftriaxone 500 mg plus azithromycin 2 g as first-line therapy. With azithromycin resistance at 7.5%, the increasing ceftriaxone MICs might soon threaten the effectiveness of this therapeutic regimen and requires close monitoring.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kirkcaldy, R. D., Harvey, A., Papp, J. R., del Rio, C., Soge, O. O., Holmes, K. K., Hook, E. W., Kubin, G., Riedel, S., Zenilman, J., et al. (2016) · MMWR Surveillance Summaries · doi:10.15585/mmwr.ss6507a1 · Cited by 249
Cited by
Unemo, M., Seifert, H. S., Hook, E. W., Hawkes, S., Ndowa, F., & Dillon, J.-A. R. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0128-6 · Cited by 524
Self-citationMachalek, D. A., Tao, Y., Shilling, H., Jensen, J. S., Unemo, M., Murray, G., Chow, E. P. F., Low, N., Garland, S. M., Vodstrcil, L. A., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30154-7 · Cited by 273
Self-citationUnemo, M., Lahra, M. M., Cole, M., Galarza, P., Ndowa, F., Martin, I., Dillon, J.-A. R., Ramon-Pardo, P., Bolan, G., & Wi, T. (2019) · Sexual Health · doi:10.1071/sh19023 · Cited by 262
Self-citationConfronting Rising STIs in the Era of PrEP and Treatment as Prevention
Ramchandani, M. S., & Golden, M. R. (2019) · Current HIV/AIDS Reports · doi:10.1007/s11904-019-00446-5 · Cited by 84
Cole, M. J., Day, M., Jacobsson, S., Amato-Gauci, A. J., Spiteri, G., Unemo, M., & T. E. G. R. P. G. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.18.2100611 · Cited by 17
Self-citation
Metadata
- Authors
- Day, M. J., Spiteri, G., Jacobsson, S., Woodford, N., Amato-Gauci, A. J., Cole, M. J., Unemo, M., Euro-GASP network, Indra, A., Huhlescu, S., Vanden Berghe, W., Crucitti, T., Hunjak, B., Nemeth Blažić, T., Kubele, J., Zákoucká, H., Žemličková, H., Berthelsen, L., Cowan, S., Hoffmann, S., Epstein, J., Viktorova, J., Ndeikoundam, N., Goubard, A., Bercot, B., Kohl, P., Buder, S., Bremer, V., Jansen, K., Tzelepi, E., Konte, V., Raftopoulos, V., Balla, E., Dudás, M., Sigmundsdóttir, G., Hauksdóttir, G. S., Igoe, D., Crowley, B., Suligoi, B., Stefanelli, P., Pakarna, G., Mavcutko, V., Reichert, P., Hoffmann, P., Barbara, C., Vella, F., Melillo, J. M., Van Dam, A., Van Benthem, B., Linde, I., Kløvstad, H., Steinbakk, M., Majewski, S., Młynarczyk-Bonikowska, B., Azevedo, J., Borrego, M.-J., Pavlik, P., Truska, P., Klavs, I., Jeverica, S., Vazquez, J., Diaz, A., Abad, R., Velicko, I., Unemo, M., Hughes, G., Templeton, K., & Irvine, N.
- Venue
- BMC Infectious Diseases
- Published
- 2018-12-03
- Volume
- 18
- Issue
- 1
- Pages
- 609-609
- ISSN
- 1471-2334 (ISSN-L)
- OpenAlex
- W2902827137
- Cited by
- 79
- References
- 1
- FWCI
- 9.33
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016. https://app.cochat.ai/papers/10.1186/s12879-018-3528-4
- The paper
- Day, M. J., Spiteri, G., Jacobsson, S., Woodford, N., Amato-Gauci, A. J., Cole, M. J., Unemo, M., Euro-GASP network, Indra, A., Huhlescu, S., Vanden Berghe, W., Crucitti, T., Hunjak, B., Nemeth Blažić, T., Kubele, J., Zákoucká, H., Žemličková, H., Berthelsen, L., Cowan, S., . . . Irvine, N. (2018). Stably high azithromycin resistance and decreasing ceftriaxone susceptibility in Neisseria gonorrhoeae in 25 European countries, 2016. BMC Infectious Diseases. https://doi.org/10.1186/s12879-018-3528-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.